| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Inventory | 380 | - |
| Other liabilities | 9 | - |
| Net cash used in operating activities | -96,130 | -57,236 |
| Proceeds from sales and maturities of investments | 621,899 | - |
| Proceeds from sales and maturities of short-term investments | - | 370,520 |
| Purchases of investments | 770,122 | - |
| Purchases of short-term investments | - | 529,852 |
| Acquisition, net of cash acquired | 21,967 | - |
| Purchases of property and equipment | 127 | 30 |
| Issuance of note receivable | - | 26,000 |
| Net cash used in investing activities | -170,317 | -185,362 |
| Proceeds from at-the-market offering, net of issuance costs | 49,001 | - |
| Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan | 5,800 | 701 |
| Deferred offering costs | -277 | -547 |
| Net cash provided by financing activities | 54,524 | 154 |
| Net (decrease) increase in cash and cash equivalents | -211,923 | -242,444 |
| Cash and cash equivalents at beginning of period | 257,068 | - |
| Cash and cash equivalents at end of period | 45,145 | - |
CG Oncology, Inc. (CGON)
CG Oncology, Inc. (CGON)